Manipal Health Enterprises recently made a significant debut on stock exchanges, listing at a 10.5% premium after raising over Rs 9,275 crore in India's second-largest IPO of 2026. This milestone marks the latest step in transforming the group into one of India's largest private healthcare networks. In his first interview since the listing, Dr. Ranjan Pai, Chairman of the Manipal Education and Medical Group (MEMG), shared insights into the company’s growth trajectory, capital allocation, and the strategic rationale behind its successful acquisitions.
From Doctor to Healthcare Titan: Ranjan Pai's Journey
Dr. Pai, originally trained as a doctor, embarked on a journey that led him to build a colossal healthcare empire. His career began with setting up a medical school in Malaysia, an experience that provided invaluable hands-on management skills. Upon returning to India, he strategically chose Bengaluru for the group’s head office, recognizing the city's potential to attract top talent.
The early 2000s saw the formal establishment of MEMG as a holding company, mirroring the Tata Group's model of assembling talent to build new businesses across education and healthcare. Pai's defining decision involved professionalizing the management of the struggling hospital business, a move that proved critical for its turnaround and future growth.
The Pivotal Role of Private Equity in Scaling Manipal Health
A significant turning point for Manipal was the introduction of private equity (PE) in 2006. Recognizing capital scarcity, PE partnerships became instrumental in attracting talent and funding ambitious expansion plans. Firms like TPG and Temasek brought not only capital but also a broader vision for growth, encouraging Manipal to think bigger. Pai dismisses the notion that private equity inherently increases healthcare costs, arguing that in India, PE focuses on improving efficiency, growing the business, and building scale through strategic acquisitions, rather than cost-cutting or price hikes.
"Private equity investors want the best outcomes. They focus on governance and processes. Companies with private equity alongside promoters are often better run than companies run only by promoters because the limited capital available to a promoter sometimes leads to shortcuts."
Manipal's journey included both successful and failed acquisition bids, such as the attempt to acquire Fortis. These experiences, though sometimes unsuccessful, taught valuable lessons in capital allocation and deal-making discipline, reinforcing the importance of not winning at all costs. The successful acquisition and subsequent integration of Columbia Asia, however, demonstrated Manipal's capability in not just acquiring but effectively integrating new assets, a critical differentiator in the sector.
Key Criteria for Attractive Hospital Acquisitions
When evaluating potential acquisitions, Manipal prioritizes several factors. Dr. Pai notes a preference for acquiring chains to gain a larger footprint, especially in areas where Manipal currently lacks presence. Key considerations include the network's location, its ability to complement existing operations, and the condition of the physical infrastructure, with a careful assessment of renovation costs. Crucially, the ability to attract and retain high-quality doctors within the acquired hospital is paramount to Manipal's strategy.
Navigating Competition and Future Expansion
In an increasingly competitive landscape, Manipal aims to stay ahead by continuing its focus on attracting and retaining top medical talent. As the network grows, its brand strength and strategic locations make it easier to draw in doctors. The group's future growth over the next five to ten years will continue to be driven by its flagship healthcare business, with significant expansion planned for Tier-II and Tier-III cities. A major area of focus is cancer care, with new hospitals equipped with bunkers and linear accelerators. The education vertical and the burgeoning health insurance industry also represent strong growth opportunities, with Pai expressing excitement about the secular growth in health insurance as India's prosperity increases.
Understanding Manipal's IPO Valuation
Addressing the 85-times P/E multiple at IPO, Dr. Pai clarified that this figure was somewhat skewed by the debt incurred from the Sahyadri acquisition. He suggested that the Enterprise Value to EBITDA (EV/EBITDA) ratio offers a more accurate comparison with peers. The IPO proceeds, primarily Rs 5,500 crore, are earmarked for debt repayment, which will naturally reduce the P/E multiple post-listing. The remaining funds will be allocated for future acquisitions and the development of greenfield hospitals, further solidifying Manipal's expansion plans.